Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Chugai
Biotech
Roche drops obesity antibody after flunked interim analysis
Trouble first started brewing back in March, when emugrobart failed to boost muscle growth in trials for two rare genetic diseases.
Darren Incorvaia
Sep 28, 2026 11:03am
Chugai drops only AI-assisted antibody from pipeline
Jan 30, 2026 10:55am
JPM26: Chugai chases new science and name recognition
Jan 16, 2026 5:28am
Roche axes 4 Chugai solid tumor assets in early-phase clear-out
Oct 23, 2025 4:53am
Chugai inks $250M deal for Gero’s age-related disease targets
Jul 7, 2025 3:00am
Roche's Chugai inks Swiss ADC deal potentially worth over $780M
Jan 8, 2025 8:00am